UroGen Pharma
UroGen Pharma is a biopharmaceutical company headquartered in Princeton, NJ, specializing in urological treatments, including the FDA-approved Jelmyto® and the RTGel® technology.
Services
UroGen Pharma provides a range of therapeutic solutions focused on urological applications. They offer Jelmyto® (mitomycin) for pyelocalyceal solution, the first FDA-approved therapy using their proprietary RTGel® technology. This gel allows for sustained drug release. Additionally, UroGen Pharma provides UGN-102 (mitomycin) for intravesical solution as a nonsurgical alternative for treating low-grade intermediate risk non-muscle invasive bladder cancer. They also have a Named Patient Program for Jelmyto® in countries where it is not yet approved.
Products
UroGen Pharma has developed RTGel® technology, a reverse-thermal hydrogel designed for sustained drug release in urological applications. Their key products include Jelmyto® (mitomycin) for pyelocalyceal solution, the first FDA-approved product utilizing RTGel®. Another significant product is UGN-102 (mitomycin) for intravesical solution, tailored for the nonsurgical treatment of low-grade intermediate risk non-muscle invasive bladder cancer. They are also engaged in developing UGN-301, an in-licensed anti-CTLA-4 antibody (zalifrelimab) for treating high-grade non-muscle invasive bladder cancer.
Location and Operations
UroGen Pharma is headquartered in Princeton, NJ with operations extending to Israel. This bi-national presence enables the company to leverage diverse expertise and resources in the field of urological therapies.
Research and Development
UroGen Pharma is heavily invested in research and development, primarily focusing on innovative treatments for bladder cancer. They are evaluating UGN-301 in combination with UGN-201 and gemcitabine in multi-arm Phase 1 studies. These efforts highlight their commitment to advancing non-surgical treatment options and improving patient outcomes in the field of uro-oncology.
Collaborations and Agreements
UroGen Pharma maintains a license and supply agreement with medac GmbH to develop next-generation mitomycin-based formulations using RTGel® technology. This collaboration aims to enhance the efficacy and delivery of mitomycin-based therapies. They also provide independent medical education grants to support continuing education in urology and uro-oncology, underlining their commitment to medical advancement and ethical business practices.